• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.

作者信息

Nagata Shunichi, Hamaji Masatsugu, Ozasa Hiroaki, Yamada Yoshito, Ohsumi Akihiro, Date Hiroshi

机构信息

Department of Thoracic Surgery, Nagara Medical Center, Gifu, Japan; Department of Thoracic Surgery, Kyoto University, Kyoto, Japan.

Department of Thoracic Surgery, Kyoto University, Kyoto, Japan.

出版信息

Clin Lung Cancer. 2022 Jul;23(5):e321-e324. doi: 10.1016/j.cllc.2022.05.002. Epub 2022 May 11.

DOI:10.1016/j.cllc.2022.05.002
PMID:35649818
Abstract
摘要

相似文献

1
Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.免疫检查点抑制剂治疗晚期非小细胞肺癌后的挽救性手术：免疫相关不良事件与更长生存期之间的潜在关联
Clin Lung Cancer. 2022 Jul;23(5):e321-e324. doi: 10.1016/j.cllc.2022.05.002. Epub 2022 May 11.
2
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.肿瘤浸润淋巴细胞密度与免疫治疗晚期非小细胞肺癌患者的良好预后相关。
Eur J Cancer. 2021 Mar;145:221-229. doi: 10.1016/j.ejca.2020.10.017. Epub 2021 Jan 27.
3
Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.纳武利尤单抗相关的史蒂文斯-约翰逊综合征 1 例合并肺癌患者
Dermatol Online J. 2021 Mar 15;27(3):13030/qt2897t6dq.
4
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.免疫治疗的晚期非小细胞肺癌患者的心包积液发生率。
Adv Ther. 2020 Jul;37(7):3178-3184. doi: 10.1007/s12325-020-01386-y. Epub 2020 May 20.
5
Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.免疫检查点抑制剂治疗晚期非小细胞肺癌患者中伴随用药对临床结局的影响：一项回顾性研究。
Thorac Cancer. 2021 Jul;12(13):1983-1994. doi: 10.1111/1759-7714.14001. Epub 2021 May 14.
6
Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.纳武利尤单抗治疗晚期非小细胞肺癌进展后。
Clin Transl Oncol. 2021 Mar;23(3):582-590. doi: 10.1007/s12094-020-02452-1. Epub 2020 Jul 13.
7
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的肺癌患者中传染病的新关注点。
Respir Med. 2019 Jan;146:66-70. doi: 10.1016/j.rmed.2018.11.021. Epub 2018 Dec 13.
8
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.免疫相关性肺炎与晚期非小细胞肺癌抗程序性细胞死亡蛋白-1 单药治疗临床获益的相关性。
Cancer Med. 2021 Jul;10(14):4796-4804. doi: 10.1002/cam4.4045. Epub 2021 Jun 13.
9
Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.纳武利尤单抗致暴发性 1 型糖尿病伴 C 肽水平急剧下降
J Diabetes Investig. 2020 May;11(3):748-749. doi: 10.1111/jdi.13143. Epub 2019 Oct 6.
10
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.免疫相关不良反应与免疫检查点抑制剂在非小细胞肺癌中的疗效相关性。
Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11.

引用本文的文献

1
Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases.肺鳞状细胞癌伴罕见驱动基因突变患者一线免疫治疗联合治疗的良好反应：三例报告
Transl Lung Cancer Res. 2025 Jun 30;14(6):2337-2346. doi: 10.21037/tlcr-2025-469. Epub 2025 Jun 26.
2
Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer.免疫检查点抑制剂治疗初始不可切除非小细胞肺癌后挽救性手术的特征与结果
J Thorac Dis. 2024 Sep 30;16(9):6094-6100. doi: 10.21037/jtd-24-891. Epub 2024 Sep 24.
3
Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.
酪氨酸激酶抑制剂/免疫检查点抑制剂治疗后挽救性手术治疗原发性肺癌的结果和病理反应。
Surg Today. 2024 Oct;54(10):1146-1153. doi: 10.1007/s00595-024-02811-3. Epub 2024 Mar 14.
4
Salvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma.恶性胸膜间皮瘤免疫治疗后的挽救性胸膜切除术/胸膜剥脱术
Interdiscip Cardiovasc Thorac Surg. 2024 Feb 2;38(2). doi: 10.1093/icvts/ivad173.
5
Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity.在免疫化疗部分缓解后治疗 IV 期非小细胞肺癌伴严重毒性患者的诱导寡转移疾病。
BMJ Case Rep. 2022 Dec 14;15(12):e252590. doi: 10.1136/bcr-2022-252590.